| Assessment Status | NCPE Assessment Process Complete |
| HTA ID | - |
| Drug | Dabigatran |
| Brand | Pradaxa® |
| Indication | For the prevention of stroke and systemic embolism in atrial fibrillation |
| Assessment Process | |
| Full submission received from Applicant | 02/11/2010 |
| NCPE assessment completed | 03/06/2011 |
| NCPE assessment outcome | Reimbursement not recommended |
03/10/2012
Following the NCPE pharmacoeconomic assessment (August 2011) the manufacturer reduced the price of dabigatran. At this revised price we now consider dabigatran cost effective for this indication.